Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation
October 04 2022 - 9:00AM
Business Wire
Lyme disease is the fastest-growing vector-borne disease in the
United States, and its increased prevalence is challenging the
scientific community to look for new ways to diagnose and treat
this worrisome infection. One answer is found in the discovery of
novel drugs; and the breakthrough efforts taking place in this
arena are the subject of a new webinar made available by Quidel
Corporation, the California-based diagnostic health care
manufacturer known for successfully developing rapid diagnostic
health solutions.
The 90-minute webinar, available free at
https://education.quidel.com/category/lyme-disease, will explain
what a small molecule drug is and how it works, identify the
methods used to unearth a new drug by high-throughput screening,
and discuss how to recognize the complexities involved in
developing a new drug for infectious disease in general. It will
also provide an overview as to the current antibiotics used for
treating Lyme disease and explore how powerful new drugs—novel
inhibitors—can selectively target Borrelia burgdorferi (the
bacterium that causes Lyme disease). The webinar is PACE-accredited
and sponsored in collaboration with Global Lyme Alliance.
Conducting the webinar is Timothy Haystead, Ph.D., professor of
pharmacology and cancer biology at Duke University School of
Medicine. Dr. Haystead’s current research is focused on the use of
chemical biology approaches to define novel drug targets. These
drug targets are focused on the treatment of hypertension, obesity,
cancer, inflammatory and infectious disease. Dr. Haystead received
his Ph.D. from the University of Dundee, Scotland; and he completed
post-doctoral work in pharmacology at the Howard Hughes Medical
Institute, University of Washington, Seattle.
The new webinar is the latest in an ongoing series sponsored by
Quidel that has featured noted scientists, researchers and
physicians discussing issues surrounding the prevalence of Lyme
disease in America, including ways to reduce the chances of
infection, early detection and treatment options. The timing and
relevance for these webinars is particularly important as Lyme
disease is on the rise to record numbers with approximately 476,000
new cases annually in the United States alone.
Quidel is the diagnostic health care manufacturer behind the
industry’s most rapid and reliable in-office test for Lyme disease,
Sofia® 2 Lyme FIA. It is the only FDA-cleared rapid point-of-care
test on the market, which provides the patient and physician with
indicative results in as few as three minutes, as opposed to days,
which has historically been the norm (and during which time
organisms can spread and become systemic). It can be performed in
the privacy of a doctor’s office or local clinic; and it is the
only test that can get results from a simple finger prick of
blood.
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading
manufacturer of diagnostic solutions at the point of care,
delivering a continuum of rapid testing technologies that further
improve the quality of health care throughout the globe. An
innovator for over 40 years in the medical device industry, Quidel
pioneered the first FDA-cleared point-of-care test for influenza in
1999 and was the first to market a rapid SARS-CoV-2 antigen test in
the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage®
and QuickVue®, Quidel’s comprehensive product portfolio includes
tests for a wide range of infectious diseases, cardiac and
autoimmune biomarkers, as well as a host of products to detect
COVID-19. With products made in America, Quidel’s mission is to
provide patients with immediate and frequent access to highly
accurate, affordable testing for the good of our families, our
communities and the world. For more information about Quidel, visit
quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221004005339/en/
Jim Yeager breakwhitelight (for Quidel Corporation)
jim@breakwhitelight.com Mobile: 818-264-6812
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From May 2024 to Jun 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2023 to Jun 2024